Skip to main content
SpringerLink
Log in

Erlotinib

Development of erlotinib resistance in non small cell lung cancer followed by disease progression and dermatotoxicity: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Faehling M, et al. Molecular profiling of EGFR-positive NSCLC with secondary T790M resistance mutation and tertiary transformation into small-cell lung cancer. Journal of Thoracic Oncology : S1259 abstr. P3.02b-109, Jan 2017 [abstract] -Germany

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erlotinib. Reactions Weekly 1658, 185 (2017). https://doi.org/10.1007/s40278-017-32382-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-32382-5

Search

Navigation